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Global responses to oxytetracycline 
treatment in tetracycline-resistant 
Escherichia coli
thea S. B. Møller1, Gang Liu1, Hassan B. Hartman2,5, Martin H. Rau3, Sisse Mortensen1, 
Kristian thamsborg1, Andreas e. Johansen1, Morten o. A. Sommer  3,4, Luca Guardabassi1, 
Mark G. poolman2 & John e. olsen  1 ✉
We characterized the global transcriptome of Escherichia coli MG1655:: tetA grown in the presence of 
½ MIC (14 mg/L) of OTC, and for comparison WT MG1655 strain grown with 1//2 MIC of OTC (0.25 mg/L 
OTC). 1646 genes changed expression significantly (FDR > 0.05) in the resistant strain, the majority 
of which (1246) were also regulated in WT strain. Genes involved in purine synthesis and ribosome 
structure and function were top-enriched among up-regulated genes, and anaerobic respiration, nitrate 
metabolism and aromatic amino acid biosynthesis genes among down-regulated genes. Blocking of the 
purine-synthesis- did not affect resistance phenotypes (MIC and growth rate with OTC), while blocking 
of protein synthesis using low concentrations of chloramphenicol or gentamicin, lowered Mic towards 
OTC. Metabolic-modeling, using a novel model for MG1655 and continuous weighing factor that 
reflected the degree of up or down regulation of genes encoding a reaction, identified 102 metabolic 
reactions with significant change in flux in MG1655:: tetA when grown in the presence of otc compared 
to growth without OTC. These pathways could not have been predicted by simply analyzing functions of 
the up and down regulated genes, and thus this work has provided a novel method for identification of 
reactions which are essential in the adaptation to growth in the presence of antimicrobials.
Tetracycline drugs are bacteriostatic antimicrobials which bind reversibly to the bacterial ribosome and interfere 
with protein translation1. The prevalence of resistance to this class has steadily increased in clinical isolates from 
both humans2,3 and animals4, roughly by 0.5% per year from 1950 to 2001 in isolates from humans5. While the 
use of tetracycline in human medicine has gradually decreased, the drug class remains among the most used in 
livestock production worldwide6.
The majority of the more than 40 genes encoding tetracycline resistance encode membrane-associated efflux 
proteins7, which selectively pumps tetracycline from the cytosol to the periplasm in exchange for a proton8. 
In E. coli, TetA and TetB are the most frequently observed tetracycline efflux pumps4,9. We have shown that a 
TetA-producing E. coli strain shows prolonged lag phase proportionally to the concentration of tetracycline in 
the growth medium, and that this concurs with increased expression of tetA10. This suggests that expression of 
the resistance mechanism or incorporation of the efflux pump into the cell-membrane constitute a burden to the 
bacterium. Similar observations of cellular adaptation in antimicrobial resistant bacteria grown in the presence 
of the drug to which they are resistant have been described for Extended Spectrum Beta-Lactamase producing 
(ESBL) E. coli11,12, methicillin resistant Staphylococcus aureus12 and colistin-resistant Klebsiella pneumoniae13, and 
interfering with these adaptive responses in certain cases re-sensitize the bacteria to the drugs11,13. It is therefore 
highly relevant to increase our understanding of the way that resistant bacteria adapt to growth in the presence of 
therapeutic concentrations of antimicrobials.
In the study of ESBL adaptation to cephalosporin treatment by Møller et al.11, a high number of genes 
encoding metabolic enzymes were shown to be significantly regulated. Understanding the importance of this 
for the metabolism is not straight forward, since the metabolic network contains a high number of redundant, 
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alternative pathways14,15. Metabolic modeling has been a central tool for solving this problem16, but traditionally 
genome scale metabolic models (GSMs) only describe the network of enzyme-catalyzed and spontaneous reac-
tions proceeding in the organism17,18, and not adaptation to changing environments19. Recently, however, several 
approaches to incorporate omic-data into modeling have been published (see for example20).
The aim of this study was to improve the understanding of the metabolic adaptations in an OTC-resistant, 
tetA encoding E. coli strain to treatment with OTC. We show that despite being highly resistant to oxytetracycline, 
adaptation to growth in the presence of the drug involves a high number of genes, and using GSM with incorpo-
ration of transcriptome data, we identify metabolic adaptations that could not have been identified simply from 
looking at the list of significantly regulated genes.
Results
Global gene responses in E. coli MG1655::tetA growing in the presence of therapeutic concen-
trations of otc. In order to study the adaptation to OTC treatment, we selected a variant of E. coli MG1655, 
where tetA, together with its natural regulator, tetR, had been cloned into the chromosome. RNA-sequencing 
was used to identify significantly up and down regulated genes, when the strain was grown in MH-2-broth with 
14 mg/L OTC in comparison to growth without OTC. The chosen OTC concentration corresponds to ½ MIC of 
the strain to OTC, and is above the peak serum concentration that is obtained in humans following treatment21.
Significant change in expression, based on a false discovery rate (FDR) < 0.05, was demonstrated for 1646 
genes, showing that either the presence of the drug in the cell cytosol or the production and incorporation of 
an increasing number of TetA-pumps caused dramatic changes in cell homeostasis. Of the significantly regu-
lated genes, 946 genes were up-regulated and 700 were down-regulated (Supplementary Material Fig. S1, and 
Tables S1 and S2). When cut-offs of Abs(Log2FC) > 2.0 alternatively Abs(Log2FC) > 1.5 were used, 149 and 333 
genes were up-regulated and 119 and 211 genes were down regulated. The changes were generally moderate in 
up-regulated genes with a maximum of Log2FC = 3.94 (14.58 fold). The most down regulated genes showed up to 
Log2FC = −7.46 (73.78 fold) change in expression (Table 1).
In order to determine whether the high number of significantly regulated genes was a direct consequence of 
expressing the resistance mechanism or a common, general response to ½ MIC treatment with OTC, we also 
characterized the response in the WT MG1655 strain to growth with ½ MIC OTC (0.25 mg/L OTC). A total of 
400 genes were only regulated in the resistant strain, suggesting that this was the number of genes associated with 
the TetA expression (see Fig. 1). On the other hand, this suggested that the majority of regulated genes were part 
of a common (presumably stress-related) response, rather than a consequence of expression of the resistance 
mechanism.
ddpX was among the up-regulated genes (Table 1). This gene encodes a D-alanyl-d-alanine dipeptidase and 
is involved in peptidoglycan synthesis. It belongs to the RpoS regulon22, which is the master stress-regulon in E. 
coli. Using the list of SigmaS controlled genes published by Weber et al.23, we searched our data for signs of RpoS 
induced stress response. rpoS itself was not significantly regulated, and among the 16 genes listed as the first-line 
adaptation to stress in this regulon, only fadB was significantly up-regulated. Since TetA is a membrane bound 
Genes – 
Up
Log FC- 
change# Function/enzyme
Genes 
down
Log FC 
change# Function/enzyme
ydcI 3.94 DNA-binding transcriptional regulator trpE −7.49 Anthranilate synthase component I
prpB 3.80 2-methyl-isocitratelyase trpD −7.17 Anthranilate synthase component II
fadB 3.74 Fatty acid oxidation complex mtr −6.43 Tryptophan/indole:H + symport permease
ycdO 3.70 Conserved protein tdcB −5.93 Threonine dehydratase
cyoA 3.70 Cytochrome O oxidase subunit II trpC −5.79 Part of tryptophan synthesis pathway
bfd 3.67 Bacterioferritin-associated ferredoxin dcuC −5.72 Dicarboxylate transporter
ndk 3.61 Nucleoside diphosphate kinase nrfC −5.62 Component of nitrite reductase complex
puuA 3.54 γ-glutamyl-putrescine synthetase nrfB −5.36 Component of nitrite reductase complex
sdhC 3.53 Component of succinate dehydrogenase nrfD −5.29 Component of nitrite reductase complex
mdtQ 3.43 Predicted outer membrane protein trpB −4.96 Tryptophan synthase, β subunit
lldP 3.40 L-lactate permease trpA −4.76 Tryptophan synthase, α subunit
sdaB 3.37 L-Serine deaminase II gudX −4.74 Predicted glucarate dehydratase
fhuF 3.32 Siderophore-iron reductase cadB −4.71 Lysine-cadaverine antiporter
tnaB 3.31 Tryptophan:H + symport permease nrfA −4.70 Component of nitrite reductase complex
efeU 3.29 Ferrous iron permease (annotated as pseudogene) tdcC −4.42 Serine/threonine:H + symport permease
ddpX 3.25 D-Ala-D-Ala dipeptidase garD −4.42 D-galactarate dehydratase
astC 3.24 Succinylornithine transaminase narH −4.41 Nitrate reductase A, β - subunit
bioB 3.23 Biotin synthase apaG −4.26 Hypothetical protein
purK 3.20 Part of purine synthesis garL −4.21 2-dehydro-3-deoxygalactarate aldolase
sdhD 3.19 Succinate dehydrogenase membrane protein hypB −4.05 Accessory protein for nickel incorporation into hydrogenase isoenzymes
Table 1. List of the 20 most up regulated and down regulated genes in E. coli MG1655::tetA growing in MH-2- 
broth with 14 mg/L oxytetracycline (OTC) compared to growth in MH-2-broth without OTC.
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pump, we specifically further looked for signs of membrane stress by analyzing regulation of the Cpx, RpoE and 
Psp-systems24–26 using the cut-off value Abs(Log2FC) > 1.5. None of the genes reported to belong to these systems 
were significantly regulated. pspE of the phage shock proteins was boarder line down-regulated (log2FC −1.44), 
however, this gene is believed to encode a thiosulphate sulfotransferase, and even though it is named phage shock 
protein E, is not considered a stress associated protein27. Together, the patterns of gene regulation did not indicate 
severe membrane stress due to incorporation of TetA pumps.
Analysis for enrichment of biological functions, molecular processes, cellular components and KEGG path-
ways was performed using genes that were up or down regulated more than Abs(Log2FC) > 2.0 to focus on the 
most highly regulated genes. MG1655::tetA was found to up-regulate biosynthesis processes related to ribonu-
cleoside and ribonucleotide production, in particular purine biosynthesis, and molecular processes and cellular 
components related to ribosome function (Supplementary Table S3). Anaerobic respiration, nitrogen metabolism 
and phenylalanine, tyrosine and tryptophan biosynthesis were in particular enriched among the down-regulated 
genes (Supplementary Table S4). The down regulation of tryptophan biosynthesis was counter-acted by trypto-
phan uptake systems being highly upregulated (tnaB see Table 1).
In total, 14 purine synthesis genes (purF, purD, purT, purN, purL, purM, purC, purE, purK, purB, purH, 
apt, ndk and prs) were up-regulated between Log2FC 3.62 and Log2FC 1.59. To analyze the significance of this 
up-regulation, single and double mutants of purN and purT were constructed. These genes encode the two redun-
dant, phosphoribosylglycinamide transformylases acting at step three in the purine biosynthesis28. Blockage of 
this step results in accumulation of glycinamide ribonucleotide (GAR) and depletion of all down-stream products, 
and is therefore considered essential for the purine synthesis28. MIC of OTC was 28–32 mg/L for MG1655::tetA, 
MG1655::tetA∆purN and MG1655::tetA∆purT, while it increased to 64 mg/L for MG1655::tetA∆purN∆purT 
(Table 2). The wild type and mutated strains grew equally well in MH-2 medium without OTC (results for 
MG1655::tetA∆purN∆purT and WT strain are shown in Fig. 2). WT and mutant strains increased significantly 
in lag phase when grown in the presence of ½ MIC OTC, however, to the same degree, and they did not differ 
significantly in growth rate, suggesting that even though the purine biosynthesis genes were highly upregulated, 
the pathway was not essential for growth in the presence of OTC (Fig. 2). A possible explanation for this observa-
tion is redundancy with the purine salvage pathways, and indeed, major genes involved in this pathway (apt and 
hpt) were significantly regulated by treatment with ½ MIC of OTC in MG1655::tetA as well as in WT MG1655 
(Supplementary Fig. S2). In minimal media (M9), the wild type and single mutant strains showed even longer lag 
phases and decreased growth rate compared to growth in MH-2. As expected, the ∆purN∆purT mutant did not 
grow in M9 media, since no purines were available in this medium (data not shown).
ndk also belongs to the purine biosynthesis system. This enzyme, which was on the list of the most highly 
upregulated genes, encodes a nucleoside diphosphate kinase which is part of the UTP and CTP biosynthesis path-
way and which also functions in pyrimidine salvage29. We also knocked out this gene and compared the growth 
phenotype and MIC to OTC to that of the MG1655::tetA. The two strains grew equally well with and without 
OTC (Fig. 2). In accordance with this, MIC of the ndk mutant (32 mg/L) was not significantly changed compared 
to MIC of the WT (28 mg/L) (Table 2).
Fifty-one ribosomal and translational genes were significantly up-regulated with Log2FC between 2.72 and 
1.53 in the presence of 14 mg/L of OTC. This included genes encoding 18 50S ribosomal subunit proteins, 14 
30S ribosomal subunit proteins and 19 tRNA synthetase genes. To investigate the importance of up-regulation 
of the protein synthesis, we added sub-MIC concentrations of chloramphenicol or gentamicin simultane-
ously with OTC. These drugs inhibit the protein synthesis by binding to the 50S and 30S ribosomal subunit, 
Figure 1. Comparison of responses by WT E. coli MG1655 (x-axis) and E. coli MG1655::tetA (y-axis) strains to 
½ MIC OTC challenge, in which FDR was less than 0.05 in at least one strain. WT E. coli MG1655 was grown 
with and without OTC at 0.25 mg/L and E. coli MG1655::tetA was grown with and without OTC at 14 mg/L. 
Red points indicate genes whose change was significant only in the E. coli MG1655, green points genes that were 
significant only in E. coli MG1655::tetA and blue points genes that changed significantly in both strains.
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respectively30,31. The MIC of OTC decreased from 32 mg/L to 8 mg/L when 2 mg/L chloramphenicol was pres-
ent and to 0.25 mg/L when 1 mg/L gentamicin was present (Table 2). In a checker-board assay, synergy, defined 
as FIC ≤ 0.532 was found between 8 mg/L OTC and 0.5 mg/L gentamicin, and 0.25 mg/L OTC and 1 mg/L gen-
tamicin (Supplementary Fig. S3). The MIC of the MG1655::tetA strain for chloramphenicol was 4 mg/L and for 
gentamicin 2 mg/L. The MICs for the WT MG1655 strain to chloramphenicol and for gentamicin were as listed 
for the MG1655::tetA strain. Combination treatment with OTC and these two drugs did not decrease MIC in the 
wild type MG1655 MIC to OTC (data not shown).
Genes involved in aromatic amino acid biosynthesis, as mentioned above, were highly down-regulated. In 
common, these amino acids are synthesized with chorismate as substrate. Chorismate is the end product of the 
Shikimate pathway. In order to analyse the importance of down-regulation of the amino acid biosynthesis genes, 
we first tried to knock-out tyrA and pheA, which both catalyzes the first step in the formation of the amino acids 
Strain
Extra antimicrobials 
addeda (mg/L) MIC
MG1655 None 0.50
MG1655 Chloramphenicol 2.0 0.50
MG1655 Chloramphenicol 1.0 0.50
MG1655 Chloramphenicol 0.5 0.50
MG1655 Gentamycin 1.0 0.50
MG1655::tetA None 28
MG1655::tetA Chloramphenicol 2.0 8
MG1655::tetA Chloramphenicol 1.0 16
MG1655::tetA Chloramphenicol 0.5 16
MG1655::tetA Gentamycin 1.0 0.25
MG1655::tetA Gentamycin 0.5 8
MG1655::tetAΔndk None 32
MG1655::tetAΔpurN None 32
MG1655::tetAΔpurT None 32
MG1655::tetAΔpurNΔpurT None 64
MG1655::tetAΔaroC None 32
MG1655::tetAΔaroB None 32
MG1655:: tetAΔndk None 32
Table 2. MIC values (mg/L) to oxytetracycline of strains investigated in the study. aAdditional antimicrobials to 
OTC added to the growth medium during the MIC testing.
Figure 2. Growth curves of E. coli MG1655::tetA with purT/purN, ndk and aroB knock outs. MG1655::tetA and 
its mutants were grown in MH-2 media without OTC and with ½ MIC of OTC for each strain on a BioScreen 
CTM. Three independent replicates were performed of the growth data; the data shown represent the means.
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from chorismate. Though several optimizations were tested, it was impossible to construct this mutant, and we 
concluded that tyrA and/or pheA are essential for growth in LB media which we used for construction of the 
mutants. It should be noted, however, that others have succeeded in constructing combined tyrA/phe mutants 
in E. coli33. Instead, we knocked out aroB and aroC, which are the last enzyme in the Shimikate pathway before 
it branches to the aromatic amino acid biosynthesis pathways. As shown in Fig. 2 (data for MG1655::tetAΔaroB 
only) the mutant grew at comparable growth rate as the wild type strain both with and without ½ MIC of OTC. 
MIC towards OTC did not differ significantly between MG1655::tetA and the two mutants (Table 2). As expected, 
the aroB and aroC mutants did not grow in M9 minimal medium due to lack of aromatic amino acids (data not 
shown).
Analysis of the secondary transcriptome to otc by metabolic modeling. In total 468 genes 
encoding metabolic enzymes were significantly up-regulated in MG1655::tetA (49.5% of up regulated genes), and 
319 genes were down regulated (44.3% of down regulated genes). This suggested that changes in the metabolism 
were a major component in the adaptation to growth in the presence of high concentrations of OTC. In order to 
investigate the metabolic significance of this we used a modeling approach. We built a genome scale model of E. 
coli K-12 MG1655 from the ecocyc database. It had a total of 1335 reactions encoded by 880 unique genes, 1335 
internal and 64 external metabolites. The model was curated to be fully balanced to all atomic species, including 
protons and was demonstrated to have no violations of conservation of energy or mass. The model was able to 
produce all biomass components of growing E. coli individually and in combination in proportions correspond-
ing to published experimental data34 (data not shown). Generating this biomass composition, using FBA to min-
imize total flux in the network and assuming growth on M9 media, the model utilized 331 of the 1351 reactions 
in the model.
We used the change in the expression of a metabolic gene to calculate a weighting factor for the reaction(s) 
associated with that gene, and when these weighting factors were applied, Flux Balance Analysis showed that 59 
reaction fluxes increased significantly and 43 decreased. Inspection of this set of reactions showed a 50% increase 
in the flux of the proton-translocating ATP synthase reaction and concomitant increases in reactions of the elec-
tron transport chain (ETC), Oxygen and glucose uptake systems and CO2 excretion systems, all pointing to a 
substantial increased energy demand resulting from OTC exposure. Other regulated reactions were primarily 
associated with central carbon metabolism in addition to reactions involved with amino acid and nucleotide 
metabolism. These reactions were then extracted to form a regulated sub-model for further analysis.
The sub-model formed from the 102 up and down regulated reactions contained a total of 50 metabolites that 
were internal to the sub-model, and 75 metabolites that were exchanged with the rest of the model (i.e. those reac-
tions whose computed fluxes did not vary in response to the weighting associated with OTC exposure). It proved 
infeasible to calculate elementary modes of the sub model, presumably because of the large number of exchange 
Figure 3. Reactions of the reduced sub-model. R1–R9, R12: E–D pathway, R13–R18: OPPP, R20–R24: OP. 
Italicised numbers are the ratio of weighted/reference solution values.
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reactions. However, as described in the methods section, it was possible to further reduce this sub-model to a 
network of 33 reactions and 50 metabolites of which 20 were exchanged with the whole model. This reduced 
sub-model had a total 94 elementary modes, and using the method described by Schuster et al.35, the flux dis-
tributions in both the weighted and un-weighted sets could be accounted for by 8 of these elementary modes as 
shown in Table 3.
The reactions used by the elementary modes comprised mainly of the Entner-Doudoroff (E-D) pathway, the 
oxidative pentose phosphate pathway (OPPP) and oxidative phosphorylation (OP). In addition to these reactions, 
the network also utilized fructose-6-phosphate aldolase, PEP-glycerone phosphotransferase and glutamate syn-
thase (R19, R11 and R25 in Fig. 3 respectively). Thus, the gene regulation pattern in response to OTC treatment 
caused the metabolism to shift flux away from the E-D pathway, and in to the OPPP and OP. Reactions 11 and 19 
(Fig. 3) only carried fluxes in the strain reference, and not in the modeling with the weighted, solution.
Discussion
Global expression analysis was performed to characterize adaptation to growth in the presence of OTC in an OTC 
resistant E. coli MG1655 strain. The strain was grown in the presence of therapeutically relevant concentrations of 
OTC and the transcriptome was used to guide metabolic modeling. Transcriptomic analysis has previously been 
used to characterize adaptive changes in cephalosporin resistant E. coli and methicillin resistant S. aureus11,12, 
while others have used a transposon guided sequencing (TraDis) approach to characterize adaptive changes in 
pan-resistant K. pneumoniae13. Together, the data has shown that even for resistant bacteria, fighting antibiotics 
is not just a matter of expressing the resistance mechanisms, but involves regulation of genes that are not part of 
the resistance mechanism, per se. The work by Brochmann et al.12 also showed that there are strains differences 
in this response, and the results of the current study should be viewed with some caution, as only one strain was 
analyzed.
OTC treatment of the resistant strain caused major changes in gene regulation, and genes belonging to 44 
different biological functions were found to be significantly regulated. The majority of the significantly regulated 
genes were also significantly regulated when WT MG1655 was treated with ½ MIC of OTC, showing that the 
main part of the response was not directly related to expression of the TetA pump. In parallel to our study, another 
transcriptome study of a tetracycline resistant E. coli, belonging to the Extra Intestinal Pathogenic E. coli group 
APEC and grown in the presence of 32 mg/L tetracycline, was published36. Our study confirms the observation 
from that study of a general up regulation of ribosome associated genes and the purine metabolism and the down 
regulation of anaerobic respiration and nitrate reduction, when grown with tetracycline. Biosynthesis of aromatic 
amino acids was not down regulated in that study, confirming strain specific differences.
TetA strains grown in the presence of high concentrations of OTC show a significant increase in lag phase, and 
this has been proposed to indicate stress due to incorporation of TetA pumps in the membrane10. In the current 
study, we did not observe indications of membrane stress. It has proved technically impossible to determine the 
number of TetA pumps in E. coli by proteomics10, and thus it is difficult to estimate whether there is a fixed upper 
number of TetA pumps that can be incorporated into the membrane, thus avoiding membrane stress.
We tested whether significantly regulated pathways were essential for expression of the resistant phenotype. 
The purine synthesis was highly up-regulated indicating that purine de novo synthesis is an important part of the 
adaptive response to OTC treatment. Similar up-regulation of purine synthesis was observed in ESBL E. coli in 
the presence of cefotaxime11, and was also shown in the recent expression study with the APEC strain36. Despite 
this, an increase in MIC in the presence of OTC was observed when purine synthesis was blocked. Purines can 
be obtained in other ways, either by uptake from the medium or by purine salvage pathways37,38. In the current 
study, important genes in the purine salvage pathway were up-regulated in the TetA strains as well as in the WT 
MG1655 in the presence of ½ MIC of OTC, and it is likely that this system can fully compensate for lack of purine 
Flux
Substrates Products0 mg/L OTC
14 mg/L 
OTC
5.76e-6 (68) 1.12e-4 Glc, O2 AcCoA, NADPH, ATP
1.05e-5 (31) 2.28e-4 AKG NH4 Glc O2 Pyr, Glt, NADPH
1.38e-5 (67) 1.84e-5 AKG, NH4, Glc Glt, AcCoA, NADPH, ATP
1.44e-5 (17) 1.84e-5 AKG, NH4, Glc Glt, AcCoA, NADPH
3.53e-5 (52) 2.44e-4 Glc, O2 Pyr, ATP
5.64e-5 (81) 8.67e-5 AKG,NH4,Glc,O2 Glt, AcCoA. NADPH, ATP
6.00e-5 (79) 1.85e-4 Glc,O2 AcCoA, NADPH, ATP
6.57e-5 (82) 3.44e-5 Glc,O2 AcCoA, NADPH, ATP
5.76e-6 (68) 1.12e-4 Glc, O2 AcCoA, NADPH, ATP
1.05e-5 (31) 2.28e-4 AKG NH4 Glc O2 Pyr, Glt, NADPH
1.38e-5 (67) 1.84e-5 AKG, NH4, Glc Glt, AcCoA, NADPH, ATP
Table 3. Simplified stoichiometries of elementary modes and their associated fluxes in the reduced sub-model 
with and without weighting factors for MG1655::tetA grown in the presence of 14 mg/L OTC compared to 
growth without OTC. Glc:glucose, AcCoA:acetyl-coenzyme A, AKG: alpha ketoclutarate, Glt:glutamate, 
Pyr:pyruvate
7Scientific RepoRtS |         (2020) 10:8438  | https://doi.org/10.1038/s41598-020-64995-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
biosynthesis under these conditions. In minimal medium, lack of the purine synthesis pathway was costlier to the 
strain judged from growth responses, and it may be that the effect of blocking purine biosynthesis in vivo (in the 
patient) is more pronounced than the growth study in MH-2 media suggests.
Protein synthesis was shown to be essential for the response of MG1655::tetA towards OTC. The MIC towards 
tetracycline decreased below the epidemiology cut-off for OTC (≤8 mg/L39) when low concentrations of the ribo-
some inhibitors chloramphenicol or gentamicin were present. MIC in the WT MG1655 strain did not decrease 
in the same way. This suggests that the mechanism was related to operating the efflux pump in the MG1655::tetA 
strain, putting high metabolic demands (presumably energy) on the resistant strain, and that this is then over-
loaded by the challenge from the second antibiotic. However, an additive effect of OTC and chloramphenicol 
on E. coli has previously been observed by Ciak and Hahn40, and confirmed by Garrett and Brown41 based on 
studies of antibiotic sensitive E. coli strains, and it may also be that the synergistic effect is too small to create 
a significant effect on MIC at the low OTC concentrations tolerated by the WT strain. To our knowledge, the 
promising effect of combining OTC and chloramphenicol with the goal of reducing OTC resistance in a highly 
resistant strain has not been reported previously. The combination of tetracycline and chloramphenicol has pre-
viously been used to treat against Streptococcus viridans infections, however, it only resulted in a partial treatment 
effect42. Furthermore, the two antibiotics showed no synergy when tested on several strains of Staphylococcus 
aureus42. Gentamicin, like OTC, targets the 30S ribosomal subunit, but with a different mode of action compared 
to OTC3,43. This could be the reason for the observed synergy. Combining gentamicin and doxycycline has been 
used as an effective combination for treatment of human brucellosis44.
Biosynthesis genes for aromatic amino acids were significantly down-regulated. To investigate the importance 
of this, and the Shikimate pathway in general, we eliminated two essential enzymes in the Shikimate pathway. 
aroB encodes the 3-dehydroquinate synthase, which is the second step in the synthesis of chorismate, while aroC 
encodes the chorismate synthase, which is the last step in the Shikimate pathway. After this step, chorismate is 
used in the biosynthesis of the aromatic amino acids45,46. All the enzymes of the Shikimate pathway are attractive 
targets for the development of anti-metabolites and antimicrobials, as the pathway is not present in mammals47,48. 
5-enolpyruvylshikimate-3-phosphate (EPSP) synthase, encoded by aroA, has been studied extensively and is the 
target by the active ingredient of the commercially available broad-spectrum herbicide RoundUp™ 49. In the cur-
rent study, no effect on growth with OTC was seen from knocking out genes of the Shikimate pathway, which is 
in accordance with the observation that biosynthesis was downregulated. For tryptophan, we saw indication that 
the down regulation of biosynthesis was counter-acted by tryptophan uptake systems being highly upregulated.
The largest group of regulated genes was metabolic enzymes. In order to investigate the metabolic network 
on a global scale, we used a novel approach where we incorporated the transcriptome date into global metabolic 
modeling. We first build an E. coli MG1655 genome scale metabolic model based on information available in 
the publicly available and standardized biochemical database, BioCyc. There is already an existing E. coli model, 
EcoCyc–18.0–GEM50, constructed from the EcoCyc database. There are important differences between these 
two models; EcoCyc–18.0–GEM is a larger model with 2286 reactions and 1453 metabolites. Most of these extra 
reactions were removed from the model presented here, owing to more stringent criteria for reaction inclusion in 
terms of metabolic relevance and atomic balance. Furthermore, a small number of reactions in our model had no 
equivalent in EcoCyc–18.0–GEM. These reactions were manually defined in the module of extra reactions (see 
methods section). The EcoCyc–18.0–GEM model has a greater number of un-conserved metabolites (1170), than 
our model. This includes compounds consisting of carbon, nitrogen, phosphate and sulfur. The model presented 
here had no un-conserved metabolites.
Methods for the integration of transcriptomic data with genome scale metabolic models have been described 
previously. The aim with all the integration methods is to obtain improved flux predictions using transcriptomic 
data, and they are based upon the assumption that the expression rate of a given gene, obtained from the exper-
imental data, is correlated with the flux through the reaction catalysed by the enzyme encoded by the gene. This 
assumption is not necessarily correct as illustrated by Yang et al.51. Different approaches have been used. Covert 
et al. used Boolean logic to evaluate whether sufficient expression had occurred for a given reaction to proceed 
in order to further constrain the FBA problem52. This may not be fully accurate, as many regulatory mechanisms 
cannot be described with Boolean logic19. Other methods, e.g. GIMME53 and iMAT54,55, are based on systematic 
removal of reactions from the model based on low transcriptomic levels. A more realistic approach was recently 
introduced be Yang et al.20, who simulated growth with incorporation of data on protein abundances. The advan-
tage of the weighting system used in the current study was that it favours reactions that are associated with high 
levels of gene expression and select against those with low expression levels, and thus the method (in contrast to 
other approaches53–55) does not depend on setting arbitrary threshold values of expression that lead to the inclu-
sion or exclusion of a given reaction. One problem with the integration of transcriptomic data into metabolic 
models consists of multi-gene and multi-reactions situations19 and that there is not necessarily a straight correla-
tion between gene and protein expression.
The modelling analysis resulted in 102 reactions whose flux changed in response to the added weighting. This 
sub-network was reduced to a more tractable size of 25 reactions. The calculated flux changes are consistent with 
an increased demand for ATP when E. coli MG1655::tetA grows in the presence of high concentrations of OCT. 
This demand is being met by changes in flux in both the Entner-Doudoroff (E-D) and oxidative pentose pathways. 
However, these flux rearrangements do not follow a conventional view of the functioning of the E-D pathway; 
although the first steps, R3-R5 increase in flux, the subsequent steps, R6-R9, decrease. This is compensated for by 
additional consumption of GAP, by increased activity in the OPPP, whose fluxes also increase. The result of these 
changes is an increased flux in reactions of the electron transport chain (ETC) and oxidative phosphorylation 
(OP) utilising the increased production of reducing equivalents.
It is also of note that in addition to reactions that might be expected to be associated with increased metabolic 
stress, the network also contains fructose-6-phosphate aldolase (R19) and dihydroxyacetone kinase (R11). Both 
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of the enzymes responsible for these reactions have been relatively recently discovered56,57 and whose metabolic 
role is as yet not clearly understood.
Of the reactions associated with the pur-genes, only one, phosphoribosyl pyrophosphate synthetase (prs) 
showed an increase in flux in the model analysis, and this response was common to both the WT and the oxy-
tetracycling resistant MG1655::tetA strain. The fact that increases in expression were not reflected in changes in 
calculated flux are not surprising for two reasons: Firstly, even if an increase in transcript level does lead to an 
increase in enzyme activity, the flux catalysed by that enzyme is a function of the activity of all enzymes in the net-
work and not that of the enzyme alone; a major motivation in the design of the model analysis was to reflect this 
interdependency. Secondly these reactions are ultimately contributing to nucleotide and amino acid components 
of the biomass, and as the proportion of these was fixed, this places additional constraints on the values that these 
reaction fluxes can take.
In summary, the results of the study showed that growth in the presence of ½ MIC of OTC resulted in pro-
found changes in gene expression in the OTC resistant E. coli MG1655::tetA. This suggests that pumping out 
of OCT using the tetracycline specific pump TetA requires highly adaptive responses, and this may render the 
bacterium vulnerable in other parts of the cell than those targeted by the OTC. Indeed, we identified combina-
tions of antibiotics (chloramphenicol and gentamycin), where even sub-therapeutic concentrations of the other 
drug were shown to increase the OTC susceptibility. The study investigated a novel approach to characterize the 
metabolic adaptation in antimicrobial resistant bacteria. It demonstrated that metabolic modeling with incor-
porated transcription data identified adaptive reactions that were not obvious from just looking at up and down 
regulated genes. On the contrary, the pathways which were identified using metabolic modeling were generally 
not controlled by enzymes encoded from genes which were among the most highly regulated genes. We suggest 
that this approach is generally applicable to studies of adaptation to antimicrobial treatment in antimicrobial 
resistant bacteria.
Methods
Bacterial strains. The strains used in this study are listed in Table 4. The OTC-resistant derivative 
of MG1655 was described in a previous study58. It has tetA gene and its repressor gene, tetR, cloned into the 
pseudo gene ybeM. Strains were maintained in DifcoTM Lysogeny broth (LB), Lennox (Becton, Dickinson and 
Company, Denmark) and on LB agar plates (Becton, Dickinson and Company, Denmark) supplemented with 
OTC (10 mg/L) (Sigma, Copenhagen, Denmark) when appropriate.
Site-specific mutants were produced by Lambda Red recombination59, resulting in exchange of the gene of 
interest with chloramphenicol or kanamycin gene cassettes. During strain construction, the medium was supple-
mented with kanamycin (30 mg/L) or chloramphenicol (10 mg/L) (Sigma, Copenhagen, Denmark) when appro-
priate. Primer sequences used for Lambda Red mediated mutagenesis and PCR verifications are listed in Table 5. 
Insertions were confirmed by PCR using standard procedures.
Antimicrobial susceptibility testing. The MICs for OTC, chloramphenicol (Sigma, Copenhagen, 
Denmark), and gentamicin (Sigma, Copenhagen, Denmark), were determined using the broth-micro-dilution 
method in the range from 0 to 512 mg/L by 2-fold dilutions increase following the CLSI guidelines, When neces-
sary, more detailed determination with more concentration steps were included, as previous described11.
checkerboard assay. Checkerboard assays were performed in Mueller-Hinton II (MH-2) (Sigma, 
Copenhagen, Denmark) broth with two different antibiotic combinations: OTC and chloramphenicol, and OTC 
and gentamicin, as previously described11. The panel was incubated aerobically at 37 °C for 18–22 hours, without 
shaking. The fractional inhibitory concentration (FIC) index was defined as; ∑FIC = FIC A + FIC B, where FIC 
A is the MIC of drug A in the combination divided by the MIC of drug A alone, and FIC B is the MIC of drug B in 
the combination divided by the MIC of drug B alone60. The antibiotic combinations were interpreted as synergetic 
when the ∑FIC ≤ 0.5, indifferent when the ∑FIC > 0.5–4, and antagonistic when the ∑FIC > 432.
Growth conditions. In order to obtain RNA for expression analysis, the strains were grown in 250 mL 
flasks containing 100 mL of MH-2 broth either without OTC or with OTC corresponding to ½ MIC of the 
OTC-resistant strain (14 mg/L) or ½ MIC of the wild type strain MG1655 (0.25 mg/L61). Growth was at 37 °C and 
with shaking (225 rpm). The flasks were inoculated with pre-cultures grown for 2 hours at 37 °C and 225 rpm to a 
final cell density of 105 CFU/mL, as determined by use of Sensititre™ Nephelometer (Thermo Scientific™) with 
a McFarland 0.5 standard. The cultures were monitored by measuring optical density until samples reached the 
logarithmic phase (OD600nm = 0.5–0.6), where aliquots were taken for RNA extraction. Biological duplicates were 
performed.
Growth for characterization of growth-responses to treatment were performed in Mueller-Hinton II (MH-
2) on a BioScreen CTM for 24 hours at 37 °C as previously described11. The cultures were supplemented with OTC 
(Sigma, Copenhagen, Denmark) representing ½ MIC of the corresponding strain when appropriate. Strains were 
also grown in M9 minimal media (2 mM MgSO4, 0.1 mM CaCl2, 0.4% glucose, 8.5 mM NaCl, 42 mM Na2HPO4, 
22 mM KH2PO4, 18.6 mM NH4Cl). Lag phase of growth curves was defined as the time necessary to reach an 
OD600 of 0.1. Statistical comparison of lag phase was performed by one-way ANOVA using GraphPad Prism. 
Growth characterization experiments were performed with three biological replicates and with three technical 
repeats for each of these.
RnA extraction. RNA extraction for RNA seq was performed essentially as previously described11. Briefly, 
3 mL cell samples were mixed with RNAlater (Ambion®, Naerum, Denmark). Total RNA was extracted from 
two independently grown samples using a FastPrep system (Qbiogene, Illkirch, France) and an RNeasy Mini kit 
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(Qiagen, Sollentuna, Sweden), and quantity and quality of RNA was determined using a NanoDrop 1000 spec-
trophotometer (Thermo Scientific, Hvidovre, Denmark). After DNase treatment (Thermo Scientific, Hvidovre, 
Denmark), rRNAs (23S and 16S) were removed by subtractive hybridization using the MICROBExpress kit 
(Ambion®, Naerum, Denmark). Removal of rRNAs was confirmed with an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Glostrup, Denmark).
Rt-qpcR. Purified RNA was reverse-transcribed into cDNA using the High Capacity cDNA Reverse 
Transcription Kit (life Technologies, Naerum, Denmark). RT-qPCR was performed using FastStart Essential 
DNA Green Master (Roche, Hvidovre, Denmark). gapA and nusG were used as reference genes. RT-qPCR was 
performed twice by two separate biological samples and the results were caiculated by the 2−∆∆CT method as 
described by Pfallf62. Primer sequences can be found in the Table 5.
Library preparation and RnA sequencing. The library for RNA-Seq was prepared using the TruSeq 
RNA Sample Preparation kit (Illumina, Little Chesterford, United Kingdom), following the manufacturer’s 
instructions. The samples were validated after each step using an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Glostrup, Denmark), and the final concentration of mRNA was measured using a Qubit 2.0 Fluorometer 
(Invitrogen, Naerum, Denmark). The libraries were sequenced using the Illumina HiSeq. 2000 platform with a 
single-end protocol, multiplexing and read lengths of 100 nt.
Mapping of reads and differential expression analysis. The analysis was made on libraries consisting 
of 2.5–3 million unique reads with a length of 100 bp. A total of 4482 genes were considered in the analysis. Reads 
were trimmed for adaptor sequences using the CLC Genomics Workbench (CLC bio, Aarhus, Denmark). The 
trimmed reads were mapped onto the E. coli MG1655 genome (RefSeq Accession No. NC_000913) as previously 
described11. Briefly, hits of reads to annotated genes were counted and all rRNA read counts were removed to 
obtain a proper normalization. The data was normalized using the conditional quantile normalization method, 
while also taking into account difference in replicate library sizes and gene GC content using edgeR biocon-
ductor software package for R63. The differential expression of each annotated mRNA transcript was calculated 
using EdgeR and significantly regulated genes were selected based on the false discovery rate (FDR) (Benjamini–
Hochberg multiple testing correction)64 using a threshold of 0.05. The resulting datasets from analysis of 
MG1655::tetA grown with and without 14 mg/L OTC and MG1655 growin with 0.25 mg/L OTC are included as 
supplementary material, Tables S5 and S6. Functional enrichment analysis using gene ontology (GO) categories 
(biological process, molecular function, cellular process, KEGG pathway) were analysed using the Cytoscape 
plugin BINGO65. EcoCyC database66 was used to further analyse the functions of differentially expressed genes.
Model construction. The E. coli K-12 MG1655 genome scale model was constructed in a modular way using 
already described techniques67,68. The final model consisted of (1) A top-level module which contain information 
about the other model modules and its prime function was to import other modules; (2) A module containing 
all the automatically generated reactions (see below); (3) A module containing all transport reactions importing 
nutrients and exporting biomass components and metabolic by-products; (4) A module containing the electron 
transport chain, and (5) A module containing additional and modified reactions.
The final GSM describes a metabolic network which can generate all E. coli biomass components from a rich 
medium (Mueller Hinton broth 2 (MH-2)), consisting of glucose, amino acids (aspartic acid, theronine, serine, 
glutamic acid, proline, glycine, alanine, cysterine, valine, methionine, isoleusine, leusine, tyrosine, phenylalanine, 
histidine, lysine, arginine and tryptophan)69,70, phosphate and O2.
Details on model construction can be seen in Supplementary Material, Table S7.
incorporation of transcriptomics data into model and analysis of model. Calculating the weighting 
factor. The weighting factor wr, for a given reaction, r, was calculated as:
wr 1 2
g
g n
lfcg
0
∏= ×
=
=
−
Strain Genotype Reference/source
MG1655 E. coli MG1655 K-12 61
MG1655::tetA E. coli MG1655 ∆ybeM::tetA 58
MG1655::tetA∆PurT E. coli MG1655 ∆ybeM::tetA∆purT::Kan This study
MG1655::tetA∆PurN E. coli MG1655 ∆ybeM::tetA ∆purN::Chl This study
MG1655::tetA ∆PurT∆PurN E. coli MG1655 ∆ybeM::tetA ∆purT::Kan ∆purN::Chl This study
MG1655::tetA∆ndk E. coli MG1655 ∆ybeM::tetA ∆ndk::Kan This study
MG1655::tetA∆aroC E. coli MG1655 ∆ybeM::tetA ∆aroC::Kan This study
MG1655::tetA∆aroB E. coli MG1655 ∆ybeM::tetA ∆aroB::Kan This study
Table 4. Bacterial strains used in this study.
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where lfcg represents the observed log fold change for any gene that codes for enzymes that catalyse reaction, r, 
and which had a FDR < 0.05. As linear programs are defined as a minimization-problem in flux balance analysis, 
the weighing factor was negated so that up-regulated genes carry a lower weighting and vice-versa. The first mul-
tiplication in the equation ensured a default weight of one in the event that there were no significantly changed 
genes for a reaction.
Defining the linear program:
min vi wi:
s t
Nv 0
v 0, ¥i {irrevs}
v bio , (1)
i
t t
. Σ .
. .





=
≥ ε
=
Stating to minimize flux, where wi is the weighting factor described above and subject to three constrains: 
The first constraint specified stead-state, the second ensured that irreversible reactions carry positive flux and the 
third constraint represents the export of biomass components. The problem was solved twice, with and without 
Primer name Sequence Application
PurN-F 5′-ATGAATATTGTGGTGCTTATTTCCGGCAACGGAAGTAATTGTGTAGGCTGGAGCTGCTTC-3′ Knockout
PurN-R 5′-TTACTCGTCGGCAGCGTAGCCCTGCGGCGGCAGACGTTGACATATGAATATCCTCCTTAG-3′ Knockout
PurN-check-F 5′-GT ATCGCACCTTCAACTGCGG-3′ Proof of knockout
PurN-check-R 5′-CGAGCAATATTGGCAGATGTCCA-3′ Proof of knockout
PurT-F 5′-ATGACGTTATTAGGCACTGCGCTGCGTCCGGCAGCAACTCGTGTAGGCTGGAGCTGCTTC-3′ Knockout
PurT-R 5′-TTAACCCTGTACTTTT ACCTGTCCGGCGGCGTGCTTCGCGCATATGAATATCCTCCTTAG-3′ Knockout
PurT-check-F 5′-TGCGCGCGGAATTAATCAGGGG-3′ Proof of knockout
PurT-check-R 5′-CGCTGGAAGCGGGCGATTAC-3′ Proof of knockout
Ndk-F 5′-ATGGCTATTGAACGTACTTTTTCCATCATCAAACCGAACGGTGTAGGCTGGAGCTGCTTC-3′ Knockout
Ndk-R 5′-TTAACGGGTGCGCGGGCACACTTCGCCTTCGCCAAAGAAA CATATGAATATCCTCCTTAG-3′ Knockout
ndk-check-F 5′-CCTTCATCAATAGTCAACGGCCCTG-3′ Proof of knockout
ndk-check-R 5’-GGGTTGAAAAAAGAAACGCCCCGG-3’ Proof of knockout
PhoA-check-F 5′-GTGTGCGCAGGTAGAAGCTTTGGAG-3′ Proof of knockout
PhoA-check-R 5′-CATGAGCGTATGCGCCCGTGATC-3′ Proof of knockout
aroC-F 5′-ATGGCTGGAAACACAATTGGACAACTCTTTCGCGTAACCAGTGTAGGCTGGAGCTGCTTC-3′ Knockout
aroC-R 5′-TGCCGTAACAGGTGATCCATTAAAACGATCGCCAGCATCGCATATGAATATCCTCCTTAG-3′ Knockout
aroC-check-F 5′-CGGCGGCGATGGTGTGTTTATGC-3′ Proof of knockout
aroC-check-R 5′-CTATCGATTGTGCGCTACCCGGC-3′ Proof of knockout
tyrA/pheA-F 5′-ATGGCTGGAAACACAATTGGACAACTCTTTCGCGTAACCAGTGTAGGCTGGAGCTGCTTC-3′ Knockout
tyrA/pheA-R 5′-ATGGTTGCTGAATTGACCGCATTACGCGATCAAATTGATG CATATGAATATCCTCCTTAG-3′ Knockout
tyrA/pheA-check-F 5′-GGGAGGCGTTTCGTCGTGTGAAAC-3′ Proof of knockout
tyrA/pheA-check-R 5′-CTTCCGAGCAACCGCGCAGTG-3′ Proof of knockout
aroB-F 5′-TTACGCTGATTGACAATCGGCAATGGCGTTAAGAACAAGCGTGTAGGCTGGAGCTGCTTC-3′ Knockout
aroB-R 5′-ATGGAGAGGATTGTCGTTACTCTCGGGGAACGTAGTTACCCATATGAATATCCTCCTTAG-3′ Knockout
aroB-check-F 5′-GATCTGCGGTTCGCCACGTTCAG-3′ Proof of knockout
aroB-check-R 5′-ACACCGCCGCGTGAAGTTCTGG-3′ Proof of knockout
Kanrev-R 5′-CCGCTTCAGTGACAACGTCGAGCACAGC-3′ Proof of knockout
apt-F 5′-CTTGCTGGTTGAGCGTTA-3′ RT-qPCR
apt-R 5′-CTGATCGGTGCCGTATTC-3′ RT-qPCR
hpt-F 5′-ATGAGTTTGTGGTGGGTTAC-3′ RT-qPCR
hpt-F 5′-TCGTCCAGCAGAATCACT-3′ RT-qPCR
gapA-F 5′-ACTGACTGGTATGGCGTTCC-3′ RT-qPCR
gapA-R 5′-GTTGCAGCTTTTTCCAGACG-3′ RT-qPCR
nusG-F 5′-GTCCGTTCGCAGACTTTAAC-3′ RT-qPCR
nusG-R 5′-GCTTTCTCAACCTGACTGAAG-3′ RT-qPCR
Table 5. Primer sequences used for Lambda Red mediated mutagenesis, PCR verifications and RT-qPCR.
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wi, and the solutions compared to identify up or down regulated reactions. This set of reaction was then used to 
construct a regulated sub-model.
Constructing regulated sub-networks. The set of reactions identified above could not a priori be guaranteed to 
represent a balanced network as a result of constant fluxes of metabolites exchanged between the regulated and 
non-regulated sub-networks. However, these could be identified by constructing a stoichiometry matrix, N’ con-
structed from the reactions in the regulated sub-network. We could then calculate:
′ = ′. ′s N v
The non-zero elements of s′ corresponded to unbalanced metabolites, and hence required additional transport 
reactions to be added to N′. Their values corresponded to the negative flux to be carried by these transporters in 
order to generate a regulated sub-network, such that:
. =N v 0r r
where Nr represents the stoichiometry matrix of the regulated sub-network with the additional transporters 
included, and vr the corresponding flux vector. In this way we generated not only fully a balanced sub-model, but 
also a corresponding steady-state flux vector.
The sub-models proved hard to analyse, presumably due to large numbers of additional transporters included, 
and correlation trees with standard algorithms for flux balance analysis were inconclusive. To solve this problem, 
we generated a new algorithm, taking advantage of the fact that our analysis had created a valid steady-state flux 
vector, and based on the assumption that any Linear Programming solution in which only a single reaction is 
fixed will represent an elementary mode (EM). The novel algorithm also generated a set of fluxes corresponding 
to reactions in the newly determined EM, so as well as identifying the EMs we could assign fluxes to them. The 
calculations were as follows: Given an initial (observed) steady-state flux vector, vobs, define an LP problem:
( )
v
i
v i
v i
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min
s t
Nv 0
0 v vobs ¥ vobs 0
s t 0 vobs ¥ vobs 0
v min ¥ vobs (2)
t
t t t
t t
targ t
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.
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ie, we set a target reaction, vtarg to the minimum (absolute) flux in vobs, and minimise the total absolute flux in the 
system subject to the constraint that no flux in the solution can take an absolute value greater than that in vobs, 
and that the sign of the reaction flux in the solution is the same as that in the observed. We can now proceed as 
shown in Fig. 4.
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